Pfizer COVID Vaccine Saved 110,000 American Lives, Study Says


By Robert Preidt HealthDay Reporter
       HealthDay Reporter

MONDAY, Could 16, 2022 (HealthDay Information) — As america mourns a million deaths from COVID-19, a brand new research signifies the grim tally might have been worse. Use of the Pfizer-BioNTech COVID-19 vaccine prevented greater than 110,000 deaths and 690,000 hospitalizations in america in 2021, researchers report.

The vaccine additionally prevented 8.7 million symptomatic circumstances of an infection and saved greater than $30 billion in well being care prices and greater than $40 billion in misplaced productiveness, the research authors famous.

“The analyses present that the Pfizer-BioNTech COVID-19 vaccine contributed substantial public well being influence within the U.S. in 2021, and had a deep impact on the trajectory of the pandemic,” mentioned Manuela Di Fusco, of Pfizer’s well being economics and outcomes analysis workforce.

The Pfizer vaccine was the primary COVID-19 shot obtainable in america. It was given to just about six in 10 individuals nationwide who have been absolutely vaccinated in 2021, in accordance with the U.S. Facilities for Illness Management and Prevention.

The findings have been printed on-line Could 15 within the Journal of Medical Economics. The entire research authors acquired funding from Pfizer both as workers, consultants or workers of corporations paid by Pfizer.

Regardless of using COVID-19 vaccines, the U.S. loss of life toll in the course of the pandemic neared a million final week.

President Joe Biden ordered U.S. flags flown at half-staff Thursday.

“We should stay vigilant in opposition to this pandemic and do every little thing we are able to to save lots of as many lives as doable,” Biden mentioned.

On this research, researchers estimated the influence of the Pfizer vaccine utilizing a mannequin, real-world knowledge and medical trial knowledge.

The mannequin used knowledge on the variety of individuals vaccinated, the effectiveness of the vaccine in numerous age teams, and the possibilities of being contaminated, growing signs and being hospitalized.

It additionally included the consequences of long COVID, the variety of working days probably misplaced on account of short-term sickness and the financial influence of untimely deaths from the illness.

The mannequin didn’t embody the influence of the extra transmissible Omicron variant that turned the dominant coronavirus pressure on the finish of the research interval.


The vaccine “was estimated to forestall hundreds of thousands of COVID-19 symptomatic circumstances, hundreds of hospitalizations and deaths, and generated billions in societal financial worth within the U.S. in 2021,” Di Fusco mentioned in a journal information launch.

The findings “spotlight the chance to proceed widespread vaccination uptake to forestall COVID-19-related illness and generate societal advantages,” she added.

Quite a few limitations might have resulted within the numbers within the research being underestimates, in accordance with Di Fusco and colleagues. These embody not factoring within the vaccine’s potential to cut back transmission of the coronavirus, the severity of circumstances and the general influence of lengthy COVID .

The researchers additionally famous that their findings cannot be utilized to different COVID-19 vaccines or teams of individuals not particularly analyzed within the research.

         Extra info

There’s extra on COVID-19 vaccines on the U.S. Facilities for Illness Management and Prevention.


SOURCE: Journal of Medical Economics, information launch, Could 16, 2022


WebMD Information from HealthDay

Copyright © 2013-2022 HealthDay. All rights reserved.


Please enter your comment!
Please enter your name here